Pharvaris (PHVS) Competitors $17.25 -0.35 (-1.99%) Closing price 04:00 PM EasternExtended Trading$17.22 -0.03 (-0.17%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. MRUS, SWTX, RNA, RARE, ACLX, PTGX, AAPG, SRRK, MTSR, and KYMRShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Merus (MRUS), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors Merus SpringWorks Therapeutics Avidity Biosciences Ultragenyx Pharmaceutical Arcellx Protagonist Therapeutics Ascentage Pharma Group International Scholar Rock Metsera Kymera Therapeutics Pharvaris (NASDAQ:PHVS) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer PHVS or MRUS? In the previous week, Merus had 1 more articles in the media than Pharvaris. MarketBeat recorded 5 mentions for Merus and 4 mentions for Pharvaris. Merus' average media sentiment score of 0.48 beat Pharvaris' score of 0.38 indicating that Merus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merus 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, PHVS or MRUS? Pharvaris has higher earnings, but lower revenue than Merus. Merus is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$145.24M-$3.01-5.73Merus$36.13M100.87-$215.33M-$4.08-12.91 Which has more risk and volatility, PHVS or MRUS? Pharvaris has a beta of -2.82, indicating that its share price is 382% less volatile than the S&P 500. Comparatively, Merus has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Is PHVS or MRUS more profitable? Pharvaris has a net margin of 0.00% compared to Merus' net margin of -506.73%. Merus' return on equity of -35.99% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -54.02% -50.36% Merus -506.73%-35.99%-29.83% Do analysts prefer PHVS or MRUS? Pharvaris presently has a consensus target price of $36.20, indicating a potential upside of 109.86%. Merus has a consensus target price of $84.64, indicating a potential upside of 60.72%. Given Pharvaris' higher possible upside, equities analysts plainly believe Pharvaris is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 Do institutionals and insiders believe in PHVS or MRUS? 96.1% of Merus shares are owned by institutional investors. 4.6% of Merus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryMerus beats Pharvaris on 11 of the 16 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$920.31M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-5.7321.1726.2519.74Price / SalesN/A262.85405.80109.12Price / CashN/A41.8936.4957.06Price / Book3.117.237.925.37Net Income-$145.24M-$55.05M$3.15B$248.34M7 Day Performance0.29%-0.74%0.95%1.25%1 Month Performance4.36%6.27%5.25%5.41%1 Year Performance-7.70%0.19%32.63%18.06% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris1.5683 of 5 stars$17.25-2.0%$36.20+109.9%-6.4%$920.31MN/A-5.7330MRUSMerus1.7903 of 5 stars$52.74-0.7%$84.64+60.5%-11.1%$3.68B$36.13M-12.9337SWTXSpringWorks Therapeutics1.4944 of 5 stars$46.97+0.0%$52.57+11.9%+24.7%$3.54B$191.59M-13.77230RNAAvidity Biosciences2.1532 of 5 stars$29.15-0.5%$66.56+128.3%-30.5%$3.53B$10.90M-9.72190RAREUltragenyx Pharmaceutical4.0503 of 5 stars$36.83-0.8%$87.00+136.2%-11.5%$3.51B$560.23M-6.261,294ACLXArcellx2.7712 of 5 stars$63.62+1.0%$111.23+74.8%+19.3%$3.47B$107.94M-21.2880Positive NewsPTGXProtagonist Therapeutics1.8738 of 5 stars$53.36+0.0%$66.10+23.9%+59.5%$3.31B$434.43M71.15120News CoverageAAPGAscentage Pharma Group InternationalN/A$37.15-0.6%N/AN/A$3.26B$134.35M0.00600Positive NewsSRRKScholar Rock4.1139 of 5 stars$33.28-2.2%$42.67+28.2%+325.2%$3.23B$33.19M-13.15140MTSRMetseraN/A$29.00-2.0%$55.00+89.7%N/A$3.11BN/A0.0081Gap DownKYMRKymera Therapeutics3.08 of 5 stars$46.29+0.9%$59.82+29.2%+46.2%$2.99B$58.89M-14.93170Trending NewsInsider TradeAnalyst RevisionGap Up Related Companies and Tools Related Companies Merus Alternatives SpringWorks Therapeutics Alternatives Avidity Biosciences Alternatives Ultragenyx Pharmaceutical Alternatives Arcellx Alternatives Protagonist Therapeutics Alternatives Ascentage Pharma Group International Alternatives Scholar Rock Alternatives Metsera Alternatives Kymera Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
